Protocol Ledger

NCT05377034 · Phase II · ACTIVE NOT RECRUITING

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Interventional Phase II clinical trial protocol NCT05377034 sponsored by National Cancer Centre, Singapore in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-26 Enrollment: 119 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05377034
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)119 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05377034
Protocol FieldVerified Registry Value
NCT IdentifierNCT05377034
Consolidated Lead SponsorNational Cancer Centre, Singapore
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment119 participants (ACTUAL)
Registered Start Date2022-10-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05377034
Hospital Research SiteLocationSite Profile
Beijing Tsinghua Changgung HospitalBeijing, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->
Shandong Cancer HospitalJinan, ChinaOpen Hospital Dossier ->
National University HospitalSingapore, SingaporeOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI